GEN Exclusives

More »

GEN News Highlights

More »
Oct 17, 2006

Lentigen Receives Grant to Evaluate the Use of Lentiviral-Engineered T Cells for Cancer Therapy

  • Lentigen obtained an NIH SBIR Phase I funding to evaluate the use of lentiviral-engineered T cells that express chimeric receptors and signaling modules to improve efficacy of cancer immunotherapies directed against the tumor-associated antigen, mesothelin.

    Mesothelin is a potentially promising target in mesothelioma, squamous cell cancers of the head and neck, and ovarian, cervical, esophageal, pancreatic, and many non-small-cell-lung cancers (NSCLC), according to Lentigen. The primary collaborator on this award is

    The ultimate goal for Lentigen and Carl H. June, M.D., of the University of Pennsylvania School of Medicine, primary collaborator on this award, will be to demonstrate that human T cells can be modified using a lentiviral delivery system to directly target cancers that express mesothelin.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...

Unable to get Jobs Listings.

More »

GEN Poll

More » Poll Results »

Lab-Grown Vaginas

Which body part do you think will be successfully engineered in the lab next?